Targeted Therapy

ACC overview

Targeted therapy in adrenocortical carcinoma (ACC) refers to systemic treatment directed at specific molecular pathways, surface targets, or adrenal-specific metabolic dependencies rather than nonspecific cytotoxic chemotherapy. Within ACC care, these approaches are generally considered in advanced, recurrent, or metastatic disease, most often after or alongside established systemic strategies such as mitotane-based therapy. The targeted-therapy landscape includes growth-factor and receptor tyrosine kinase programs, antiangiogenic multikinase inhibitors, mTOR and cell-cycle approaches, cholesterol-handling and steroidogenic pathway targets, and emerging antibody-based or other biomarker-directed strategies.¹

The field has been shaped by a persistent gap between biologic rationale and clinical validation. ACC frequently shows pathway dysregulation that appears actionable, but durable benefit from single-agent targeted therapy in unselected patients has generally been limited, and few approaches have progressed to practice-changing evidence.¹ Most data are derived from preclinical studies, small retrospective cohorts, non-comparative prospective series, or review-based synthesis rather than definitive randomized trials, which limits confidence in comparative effectiveness and patient selection.¹

A central challenge is that molecular overexpression does not necessarily indicate therapeutic dependency. ACC is biologically heterogeneous, resistance pathways are common, and concomitant mitotane may alter drug exposure and interpretation of endocrine or radiographic response. As a result, targeted therapy currently remains more important as a framework for translational research and selected later-line treatment than as a uniformly established standard across ACC populations.¹

Diagnostic and Therapeutic Context

Targeted therapy is usually considered within the broader management of advanced ACC rather than as a replacement for surgery or standard systemic backbones. In localized disease, complete resection remains the principal curative modality, while in metastatic disease mitotane, cytotoxic combinations, and other systemic approaches continue to anchor routine care. Targeted agents are therefore evaluated mainly for refractory disease, for biologically defined subsets, or as investigational combination partners.¹

This context helps explain why interpretation of the literature requires caution. Reliable conclusions are strongest when a signal is seen repeatedly across translational and clinical settings, but much of the current evidence remains hypothesis-generating. The practical implication is that targeted therapy in ACC is best understood as a set of candidate strategies with uneven maturity rather than a single validated treatment class.¹

Major Target Classes

Growth-factor and receptor tyrosine kinase pathways

Growth-factor signaling has long been central to targeted-therapy development in ACC. IGF-axis biology, especially the prominence of IGF2-related signaling in ACC, provided one of the earliest and strongest mechanistic rationales for pathway-directed therapy, while VEGF/VEGFR and broader multikinase antiangiogenic approaches have supplied some of the more clinically encouraging later-line signals. EGFR, FGFR, and cMET-related programs have also been explored as part of this receptor tyrosine kinase landscape.¹

The most reliable conclusion is that these pathways are biologically relevant, but pathway relevance has not consistently translated into durable monotherapy benefit across unselected patients. Clinically, this suggests that receptor tyrosine kinase targeting may have a role in selected advanced cases or trials, but broad empiric use remains weakly supported without better biomarkers or combination strategies.¹

Historical attempts to interfere with trophic signaling predate modern selective inhibitors. An early suramin case illustrates that nonspecific growth-factor blockade was explored decades ago, but such anecdotal experience provides little direct evidence for current clinical decision-making beyond showing the longstanding interest in this therapeutic concept.²

Beyond receptor tyrosine kinases

More recent research has expanded beyond receptor tyrosine kinases into pathways that may be more closely tied to adrenal biology. These include mTOR signaling, Wnt-pathway concepts, SF1-related programs, cell-cycle and mitotic regulators, stress-response pathways, and cholesterol-handling targets such as ACAT1/SOAT1.¹ This broader map reflects a shift from general anticancer kinase inhibition toward mechanisms that may better capture steroidogenic or adrenal-specific dependencies.

What appears reliable is the conceptual importance of these pathways in translational ACC research. What is less reliable is whether any one target defines a sufficiently stable therapeutic vulnerability across clinically heterogeneous tumors. The practical implication is that these classes are most relevant for biomarker-enriched studies, rational combinations, and research on resistance rather than for routine off-protocol use.¹

Evidence Pattern and Clinical Signals

Across target classes, the literature suggests that disease stabilization is more commonly reported than deep or durable tumor regression. This pattern is consistent with the broader experience in rare solid tumors where targeted therapy is often tested in heavily pretreated populations and without molecular selection. Review-level synthesis indicates that some multikinase approaches have generated the most encouraging clinical signals, whereas several biologically compelling pathways have remained clinically unsettled despite strong laboratory rationale.¹

This unevenness is one of the most reproducible features of the field. It is reasonably reliable to say that targeted therapy may benefit a subset of patients, particularly in later-line settings, but it is not reliable to infer that pathway expression alone predicts response. In practice, treatment decisions usually require comparison against other systemic options, consideration of prior mitotane exposure, and preference for clinical-trial enrollment when feasible.¹

Limitations and Pitfalls

Several recurring limitations complicate interpretation of ACC targeted-therapy studies. Sample sizes are typically very small, retrospective selection bias is common, and the rarity of ACC restricts randomized or biomarker-stratified trial design. In addition, ACC often shows overlapping pathway activation, intratumoral heterogeneity, and adaptive escape signaling, all of which may weaken single-agent efficacy even when a target appears biologically plausible.¹

Pharmacologic confounding is also important. Mitotane may alter the metabolism and exposure of coadministered agents, making both toxicity and efficacy harder to interpret. The practical implication is that apparently negative or modest results do not necessarily invalidate a target, but they do limit generalizability and support a preference for combination strategies, pharmacokinetic awareness, and stronger biomarker development.¹

Role in Management and Research

At present, targeted therapy occupies a selective and largely noncurative role in ACC management. Compared with surgery in localized disease or with established systemic backbones in advanced disease, targeted agents have a more limited evidence base and are used primarily in refractory settings, investigational protocols, or rare biomarker-informed scenarios.¹

The clearest current role of this literature is in structuring research priorities. It identifies recurrent biologic programs worth testing, clarifies why many plausible targets have not translated into broad clinical benefit, and supports movement toward molecular stratification rather than expecting uniform efficacy from any single targeted class. For researchers and clinicians, the most defensible interpretation is that targeted therapy in ACC remains an evolving translational domain whose future value will likely depend on biomarker-defined subsets, rational combinations, and more robust prospective study designs.¹

See Also

• systemic_therapy_backbone
• immunotherapy
• precision_medicine_and_biomarker_development
• molecular_biology_and_tumor_evolution
• clinical_trials_and_evidence_gaps

Included Articles

• PMID 2566771: A 1989 case report described suramin treatment in a patient with ACC. The report is mainly of historical interest because it represents an early, nonspecific growth-factor–targeted approach rather than a mature or biomarker-guided ACC strategy.²

• PMID 27119750: A 2016 review situates ACC targeted therapy as broader than RTK programs alone, highlighting Wnt-pathway, SF1, mTOR, and ACAT1/SOAT1-directed strategies alongside disappointing monotherapy TKI experience. It supports the note’s emphasis on biologic plausibility outpacing validated clinical benefit while adding a clearer overview of emerging non-RTK target classes.¹

References

Footnotes

1. Novel targeted therapies in adrenocortical carcinoma.. Curr Opin Endocrinol Diabetes Obes. 2016. PMID: 27119750. Local full text: 27119750.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷

2. Effect of suramin in a patient with adrenocortical carcinoma.. Lancet. 1989. PMID: 2566771. Local full text: 2566771.md ↩ ↩²